Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 8, keine Gesamtzahl für „significant“
Suchtreffer
Begriffe & Kennungen
Dovato · 4.5 · Clinically significant interaction unlikely. Cimetidine Interaction not studied. No dosage adjustment necessar
Eintrag öffnenDuavive · 4.5 · Hormone contraceptives containing oestrogens have been shown to significantly decrease plasma concentrations o
Eintrag öffnenDuavive · 4.5 · There were no significant pharmacokinetic interactions between bazedoxifene and the following medicinal produc
Eintrag öffnenDynastat · 4.5 · Coadministration of valdecoxib and lithium produced significant decreases in lithium serum clearance (25%) and
Eintrag öffnenDynastat · 4.5 · Coadministration of valdecoxib and lithium produced significant decreases in lithium serum clearance (25%) and
Eintrag öffnenDzuveo · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Significant respir
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Bevacizumab: there was no clinically significant effect of bevacizumab on the pharmacokinetic parameters of ca
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Brivudine: a clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.5 · Oxaliplatin: no clinically significant differences in exposure to capecitabine or its metabolites, free platin
Eintrag öffnenEcansya (previously Capecitabine Krka) · 4.8 · 16 significantly associated with an increased risk of developing diarrhoea: increasing capecitabine starting d
Eintrag öffnenEdarbi · 4.5 · No clinically significant interactions have been reported in studies of azilsartan medoxomil or azilsartan giv
Eintrag öffnenEdurant · 4.3 · EDURANT should not be co-administered with the following medicinal products, as significant decreases in rilpi
Eintrag öffnenEdurant · 4.3 · EDURANT should not be co-administered with the following medicinal products, as significant decreases in rilpi
Eintrag öffnenEdurant · 4.5 · (induction of CYP3A enzymes) Rifapentine Not studied. Significant decreases Rilpivirine must not be used in in
Eintrag öffnenEdurant · 4.5 · (induction of CYP3A enzymes) Rifapentine Not studied. Significant decreases Rilpivirine must not be used in in
Eintrag öffnenEdurant · 4.5 · (reduced absorption due to gastric pH increase) Lansoprazole Not studied. Significant decreases Rabeprazole in
Eintrag öffnenEdurant · 4.5 · (reduced absorption due to gastric pH increase) Lansoprazole Not studied. Significant decreases Rabeprazole in
Eintrag öffnenEfavirenz Teva · 4.3 · Co-administration with elbasvir (EBR) and grazoprevir (GZR) due to the potential for significant decreases in
Eintrag öffnenEfavirenz Teva · 4.5 · Antiparasitics Praziquantel Significant decrease in plasma Concomitant use with concentrations of praziquantel
Eintrag öffnenEfavirenz Teva · 4.5 · Efavirenz: No clinically significant pharmacokinetic change. Posaconazole/efavirenz Posaconazole: Concomitant
Eintrag öffnen